Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
Metsera stock bidding war intensifies as Novo and Pfizer race to secure next-gen obesity drug assets amid surging market ...
The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential ...
People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their cells into tiny factories that churn out a protein that is essentially the ...
New research shows that a new weight-loss drug called MariTide might offer a powerful alternative to current weekly ...
The menopausal transition is a pivotal time in women’s health, bringing about profound hormonal, metabolic and physiologic ...
November, single-dose vials of the popular weight-loss jab—Zepbound (tirzepatide)—will be available to buy from Walmart pharmacies across the U.S., thanks to a new collaboration between the retailer ...
The partnership between LillyDirect and Walmart allows patients to pick up Zepbound at Walmart pharmacies at the same self-pay price as online. Sel ...
A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...
The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are looking for stocks to buy and hold for 30 years, here are two no-brainer names ...
Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...
A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access the super-popular weight loss drug Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback